Robin Hallett

Robin is responsible for preclinical development at POINT. He is an experienced leader in drug discovery and development with broad expertise from early discovery through to first-in-human studies. Previously, Robin was Head of Translational Sciences at Northern Biologics, which focused on developing first-in-class biologics for the treatment of solid tumors. Robin obtained his Ph.D. in biochemistry from McMaster University and completed post-doctoral training at the Hospital for Sick Children in cancer biology.